This month at Precision Medicine Thursday at Venture Café, Marco Colonna and David Holtzman will discuss genetic risk factors for Alzheimer’s disease and the development of potential therapeutics that target these genes. Colonna will speak about the role of the TREM2 gene in the development of early onset dementia and Alzheimer’s disease and testing of cytokine IL-34 as a therapeutic target for neurodegenerative diseases. Holtzman will discuss the Apolipoprotein E (ApoE) gene which is the strongest genetic risk factor for Alzheimer’s disease. He will discuss how ApoE4 strongly increases Alzheimer’s disease risk while apoE2 decreases risk and has the potential to slow down the progression of cognitive decline due to Alzheimer’s disease.
If you are a member of the WashU community, login with your WUSTL Key to interact with events, personalize your calendar, and get recommendations.Login with WUSTL Key
If you are not a member of the WashU community, please login via one of the options below to interact with our calendar.